Xiuning Le, M.D., Ph.D.
Department of Thoracic-Head & Neck Med Onc, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Assistant Professor, Department of Thoracic/Head and Neck Medical Oncology, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2010 | Harvard Medical School, Boston, MA, USA, PHD, Biological and Biomedical Sciences |
| 2003 | Peking Union Medical College, Beijing, CHN, MD, Clinical Medicine |
Postgraduate Training
| 2014-2017 | Research Fellowship, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA |
| 2013-2016 | Clinical Fellowship, Hematology Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA |
| 2010-2013 | Clinical Residency, Internal Medicine, University of Massachusetts Medical Center, Worcester, MA |
Board Certifications
| 2016 | American Board Internal Medicine, Medical Oncology |
| 2013 | American Board Internal Medicine, Internal Medicine |
Experience & Service
Academic Appointments
Instructor, Department of Hematology Oncology, Division of Internal Medicine, Beth Israel Deaconess Medical Center, Boston, MA, 2016 - 2017
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Liu X, Hong L, Nilsson M, Hubert SM, Wu S, Rinsurongkawong W, Lewis J, Spelman A, Roth J, Swisher S, He Y, Jack Lee J, Fang B, Heymach JV, Zhang J, Le X. Concurrent use of aspirin with osimertinib is associated with improved survival in advanced EGFR-mutant non-small cell lung cancer. Lung Cancer 149:33-40, 2020. e-Pub 2020. PMID: 32956986.
- Nilsson MB, Sun H, Robichaux J, Pfeifer M, McDermott U, Travers J, Diao L, Xi Y, Tong P, Shen L, Hofstad M, Kawakami M, Le X, Liu X, Fan Y, Poteete A, Hu L, Negrao MV, Tran H, Dmitrovsky E, Peng D, Gibbons DL, Wang J, Heymach JV. A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components. Sci Transl Med 12(559), 2020. PMID: 32878980.
- Paik PK, Felip E, Veillon R, Sakai H, Cortot AB, Garassino MC, Mazieres J, Viteri S, Senellart H, Van Meerbeeck J, Raskin J, Reinmuth N, Conte P, Kowalski D, Cho BC, Patel JD, Horn L, Griesinger F, Han JY, Kim YC, Chang GC, Tsai CL, Yang JC, Chen YM, Smit EF, van der Wekken AJ, Kato T, Juraeva D, Stroh C, Bruns R, Straub J, Johne A, Scheele J, Heymach JV, Le X. Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations. N Engl J Med 383(10):931-943, 2020. e-Pub 2020. PMID: 32469185.
- Carrot-Zhang J, Chambwe N, Damrauer JS, Knijnenburg TA, Robertson AG, Yau C, Zhou W, Berger AC, Huang KL, Newberg JY, Mashl RJ, Romanel A, Sayaman RW, Demichelis F, Felau I, Frampton GM, Han S, Hoadley KA, Kemal A, Laird PW, Lazar AJ, Le X, Oak N, Shen H, Wong CK, Zenklusen JC, Ziv E, Cancer Genome Atlas Analysis Network, Cherniack AD, Beroukhim R. Comprehensive Analysis of Genetic Ancestry and Its Molecular Correlates in Cancer. Cancer Cell 37(5):639-654.e6, 2020. PMID: 32396860.
- Jin Y, Bao H, Le X, Fan X, Tang M, Shi X, Zhao J, Yan J, Xu Y, Quek K, Elamin YY, Zhang J, Futreal PA, Wistuba II, Heymach JV, Lou G, Shao L, He Q, Lin C, Wu X, Shao YW, Wang X, He J, Chen Y, Stebbing J, Chen M, Zhang J, Yu X. Distinct co-acquired alterations and genomic evolution during TKI treatment in non-small-cell lung cancer patients with or without acquired T790M mutation. Oncogene 39(9):1846-1859, 2020. e-Pub 2019. PMID: 31754213.
- Robichaux JP, Elamin YY, Vijayan RSK, Nilsson MB, Hu L, He J, Zhang F, Pisegna M, Poteete A, Sun H, Li S, Chen T, Han H, Negrao MV, Ahnert JR, Diao L, Wang J, Le X, Meric-Bernstam F, Routbort M, Roeck B, Yang Z, Raymond VM, Lanman RB, Frampton GM, Miller VA, Schrock AB, Albacker LA, Wong KK, Cross JB, Heymach JV. Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity. Cancer Cell 36(4):444-457.e7, 2019. e-Pub 2019. PMID: 31588020.
- Le X, Puri S, Negrao MV, Nilsson MB, Robichaux J, Boyle T, Hicks JK, Lovinger KL, Roarty E, Rinsurongkawong W, Tang M, Sun H, Elamin Y, Lacerda LC, Lewis J, Roth JA, Swisher SG, Lee JJ, William WN, Glisson BS, Zhang J, Papadimitrakopoulou VA, Gray JE, Heymach JV. Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC. Clin Cancer Res 24(24):6195-6203, 2018. e-Pub 2018. PMID: 30228210.
- Jiang T, Su C, Ren S, Cappuzzo F, Rocco G, Palmer JD, van Zandwijk N, Blackhall F, Le X, Pennell NA, Zhou C, written on behalf of the AME Lung Cancer Collaborative Group. A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative Group. J Thorac Dis 10(7):3909-3921, 2018. PMID: 30174832.
- Rangachari D, Le X, Shea M, Huberman MS, VanderLaan PA, Kobayashi SS, Costa DB. Cases of ALK-Rearranged Lung Cancer with 5-Year Progression-Free Survival with Crizotinib as Initial Precision Therapy. J Thorac Oncol 12(11):e175-e177, 2017. e-Pub 2017. PMID: 28611010.
- Le X, Rangachari D, Costa DB. Moving more potent and less toxic options to the frontline in the management of advanced lung cancer. J Thorac Dis 9(9):2812-2818, 2017. PMID: 29221246.
- Le X, Pugach EK, Hettmer S, Storer NY, Liu J, Wills AA, DiBiase A, Chen EY, Ignatius MS, Poss KD, Wagers AJ, Langenau DM, Zon LI. A novel chemical screening strategy in zebrafish identifies common pathways in embryogenesis and rhabdomyosarcoma development. Development 140(11):2354-64, 2013. e-Pub 2013. PMID: 23615277.
- Le X, Nilsson M, Goldman J, Reck M, Nakagawa K, Kato T, Ares LP, Frimodt-Moller B, Wolff K, Visseren-Grul C, Heymach JV, Garon EB. Dual EGFR/VEGF pathway inhibition: a promising strategy for patients with EGFR-mutant NSCLC. J Thorac Oncol. e-Pub 2020. PMID: 33096270.
Grant & Contract Support
| Title: | Project 2: Novel therapeutic strategies to enhance antitumor immunity immunologically inert subgroups of non-small cell lung cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-Investigator |
| Title: | Understanding the impact of anti-VEGF therapy on resistance mechanisms and immune modulation in EGFR-mutant NSCLC |
| Funding Source: | ASCO Conquer Cancer Foundation |
| Role: | Principal Investigator |
| Title: | Overcoming resistance to dual VEGF/EGFR inhibition in EGFR-mutant NSCLC |
| Funding Source: | Khalifa Scholar Award |
| Role: | Principal Investigator |
| Title: | Development of Novel immunothrapy for EGFR-mutant NSCLC |
| Funding Source: | Rexanna's Foundation |
| Role: | Principal Investigator |